{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:34:32Z","timestamp":1790498072619,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ctrv.2019.101909","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:24:59Z","timestamp":1570649099000},"page":"101909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status"],"prefix":"10.1016","volume":"80","author":[{"given":"Federica","family":"Tomao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6534-0063","authenticated-orcid":false,"given":"Erlisa","family":"Bardhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Di Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Maria","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocenza","family":"Palaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi Benedetti","family":"Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7353","key":"10.1016\/j.ctrv.2019.101909_b0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2019.101909_b0010","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-018-3532-9","article-title":"PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer","volume":"81","author":"Morgan","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ctrv.2019.101909_b0015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2019.101909_b0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/1758834017718775","article-title":"Niraparib in ovarian cancer: results to date and clinical potential","volume":"9","author":"Caruso","year":"2017","journal-title":"TherAdv Med Oncol."},{"key":"10.1016\/j.ctrv.2019.101909_b0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2019.101909_b0030","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101909_b0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/1078-0432.CCR-11-1973","article-title":"Iniparibnonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor","volume":"18","author":"Liu","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ctrv.2019.101909_b0040","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101909_b0045","doi-asserted-by":"crossref","unstructured":"Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADPribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA 2011; 108(8):3406\u201311.","DOI":"10.1073\/pnas.1013715108"},{"issue":"12","key":"10.1016\/j.ctrv.2019.101909_b0050","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly(ADP-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J ClinOncol"},{"issue":"5","key":"10.1016\/j.ctrv.2019.101909_b0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-016-0515-z","article-title":"What is the place of PARP inhibitors in ovarian cancer treatment?","volume":"18","author":"Liu","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2019.101909_b0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2019.101909_b0065","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions.Version 5.1.0.Wiley-Blackwell; 2008. Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011;343(oct18 2). d5928-d.","DOI":"10.1136\/bmj.d5928"},{"issue":"2","key":"10.1016\/j.ctrv.2019.101909_b0070","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","article-title":"Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias","volume":"39","author":"Knobloch","year":"2011","journal-title":"J Craniomaxillofac Surg"},{"issue":"15","key":"10.1016\/j.ctrv.2019.101909_b0075","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2019.101909_b0080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2019.101909_b0085","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a doubleblind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2019.101909_b0090","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"10106","key":"10.1016\/j.ctrv.2019.101909_b0095","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2019.101909_b0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2018.03.004","article-title":"Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer","volume":"66","author":"Musella","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"10.1016\/j.ctrv.2019.101909_b0105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12967-016-1027-1","article-title":"Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment","volume":"15","author":"Papa","year":"2016","journal-title":"J Transl Med."},{"issue":"17","key":"10.1016\/j.ctrv.2019.101909_b0110","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J ClinOncol"},{"issue":"2","key":"10.1016\/j.ctrv.2019.101909_b0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ygyno.2012.05.001","article-title":"Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma","volume":"126","author":"Hyman","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2019.101909_b0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2019.101909_b0125","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/OTT.S102569","article-title":"Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer","volume":"10","author":"Hollis","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2019.101909_b0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2018.08.011","article-title":"The Era of PARP inhibitors in ovarian cancer: \u201cClass Action\u201d or not? A systematic review and meta-analysis","volume":"131","author":"Staropoli","year":"2018","journal-title":"Crit Rev OncolHematol"},{"issue":"4","key":"10.1016\/j.ctrv.2019.101909_b0135","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000486418","article-title":"PARP (Poly(ADP-Ribose) Polymerase) inhibitors in platinum-sensitive recurrent ovarian cancer: a meta-analysis of randomized controlled trials","volume":"41","author":"Al Hadidi","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ctrv.2019.101909_b0140","unstructured":"A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO). Ongoing, NCT number 03106987, ClinicalTrials.gov."},{"issue":"26","key":"10.1016\/j.ctrv.2019.101909_b0145","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219301264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219301264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:20:40Z","timestamp":1759656040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737219301264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":29,"alternative-id":["S0305737219301264"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101909","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101909"}}